These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11206608)

  • 1. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
    Garver DL; Holcomb JA; Christensen JD
    J Clin Psychiatry; 2000 Dec; 61(12):964-72; quiz 973. PubMed ID: 11206608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?
    Garver DL; Steinberg JL; McDermott BE; Yao JK; Ramberg JE; Lewis S; Kingsbury SJ
    Neuropsychopharmacology; 1997 Mar; 16(3):191-201. PubMed ID: 9138435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative symptoms of familial schizophrenia breed true in unstable (vs. stable) cerebral-ventricle pedigrees.
    Filbey FM; Holcomb J; Nair TR; Christensen JD; Garver DL
    Schizophr Res; 1999 Jan; 35(1):15-23. PubMed ID: 9988837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
    Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
    Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
    Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response.
    Garver DL; Nair TR; Christensen JD; Holcomb J; Ramberg J; Kingsbury S
    Neuropsychopharmacology; 1999 Jul; 21(1):82-92. PubMed ID: 10379522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between plasma homovanillic acid and outcome in patients with psychosis spectrum disorders.
    van de Kerkhof NW; Fekkes D; van der Heijden FM; Egger JI; Verhoeven WM
    Neuropsychobiology; 2015; 71(4):212-7. PubMed ID: 26279280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
    Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
    Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
    Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-resistant schizophrenia--the role of clozapine.
    Meltzer HY
    Curr Med Res Opin; 1997; 14(1):1-20. PubMed ID: 9524789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
    Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
    Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
    Velakoulis D; Wood SJ; Wong MT; McGorry PD; Yung A; Phillips L; Smith D; Brewer W; Proffitt T; Desmond P; Pantelis C
    Arch Gen Psychiatry; 2006 Feb; 63(2):139-49. PubMed ID: 16461856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
    J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period.
    Sharma RP; Javaid JI; Davis JM; Janicak PG
    Biol Psychiatry; 1998 Sep; 44(6):488-92. PubMed ID: 9777181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.